Highlights of Vosoritide Program - Vosoritide is the FDA approved drug for the treatment of Achondroplasia - Developed by Biomarin, and received orphan designation from FDA and EMA - New Drug Application Under Review by FDA with Set PDUFA August 2020 - EMA validated the marketing authorization application - Publication of positive outcome data from Phase 3 study in Lancet Achondroplasia is the most common form of disproportionate short stature in humans, it is characterized by slowing of endochondral ossification, which results in disproportionate short stature and disordered architecture in the long bones, spine, face, and base of the skull. This condition is caused by a mutation in the fibroblast growth factor receptor 3 gene (FGFR3), a negative regulator of bone growth. Beyond disproportionate short stature...